Plasma exosome‑encapsulated microRNA‑21 and microRNA‑92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer

Soeda,Naruyoshi; Iinuma,Hisae; Suzuki,Yusuke; Tsukahara,Daisuke; Midorikawa,Hironori; Igarashi,Yuichi; Kumata,Yoshimasa; Horikawa,Masahiro; Kiyokawa,Takashi; Fukagawa,Takeo; Fukushima,Ryoji

doi:10.3892/ol.2019.10807

Plasma exosome‑encapsulated microRNA‑21 and microRNA‑92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer

Authors:
- Naruyoshi Soeda
- Hisae Iinuma
- Yusuke Suzuki
- Daisuke Tsukahara
- Hironori Midorikawa
- Yuichi Igarashi
- Yoshimasa Kumata
- Masahiro Horikawa
- Takashi Kiyokawa
- Takeo Fukagawa
- Ryoji Fukushima
View Affiliations

Affiliations: Department of Surgery, Teikyo University School of Medicine, Itabashi, Tokyo 173‑0003, Japan
Published online on: September 4, 2019 https://doi.org/10.3892/ol.2019.10807
Pages: 4467-4480
Copyright: © Soeda et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In patients with gastric cancer (GC), peritoneal recurrence is a common risk and associated with poor prognosis. A novel biomarker for the prediction of high‑risk peritoneal recurrence in patients with GC is desirable. The present study investigated the effectiveness of exosome‑encapsulated microRNAs (ex‑miRNAs) as minimally invasive biomarkers in patients with GC that received curative surgery. Recurrence‑specific ex‑miRNAs were selected following comparison of miRNA microarray data from patients with TNM stage II GC with peritoneal recurrence (n=3) and without peritoneal recurrence following curative surgery (n=3), and three healthy volunteers. In this analysis, exosome‑encapsulated miRNA‑21 (ex‑miR‑21) and exosomal miR‑92a (ex‑miR‑92a) exhibited the greatest alterations in expression patterns. Using plasma exosome samples collected from another 129 patients with stage II and III GC, the present study investigated the potential value of ex‑miR‑21 and ex‑miR‑92a as biomarkers. Ex‑miRNA levels were measured using TaqMan miRNA assays. Ex‑miR‑21 levels were significantly higher and ex‑miR‑92a levels were significantly lower in samples from patients with GC compared with healthy controls. The overall survival (OS) and peritoneal recurrence‑free survival (PRFS) were poorer in stage II and III patients with high ex‑miR‑21 levels than in patients with low miR‑21 levels. OS and PRFS of stage II and III patients with low ex‑miR92a levels were significantly worse than those with high ex‑miR92a levels. Cox multivariate analyses indicated that ex‑miR‑21 and ex‑miR‑92a were independent prognostic factors for OS and PRFS in stage II and III GC. A negative correlation was detected between expression levels of miR‑21 and programmed cell death protein 4 mRNA, and miR‑92a and prostaglandin E receptor 4 mRNA. Therefore, ex‑miR‑21 and ex‑miR‑92a may function as effective and minimally invasive biomarkers for the prediction of peritoneal recurrence and the prognosis of patients with stage II/III GC.

View Figures

View References

1	Hundahl SA, Menck HR, Mansour EG and Winchester DP: The National Cancer Data Base report on gastric carcinoma. Cancer. 80:2333–2341. 1997. View Article : Google Scholar : PubMed/NCBI
2	Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI
3	Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI
4	Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G and Miwa K: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 178:256–262. 1999. View Article : Google Scholar : PubMed/NCBI
5	Chen KB, Chen J, Jin XL, Huang Y, Su QM and Chen L: Exosome-mediated peritoneal dissemination in gastric cancer and its clinical applications. Biomed Rep. 8:503–509. 2018.PubMed/NCBI
6	Sugarbaker PH and Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncology. 58:96–107. 2000. View Article : Google Scholar : PubMed/NCBI
7	Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, et al: Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 36:1922–1929. 2018. View Article : Google Scholar : PubMed/NCBI
8	Jeung HC, Rha SY, Jang WI, Noh SH and Chung HC: Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg. 89:460–466. 2002. View Article : Google Scholar : PubMed/NCBI
9	Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, Yonemura Y and Baba H: Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 250:242–246. 2009. View Article : Google Scholar : PubMed/NCBI
10	Liang P and Hu X: Strategies of diagnosis and treatment for peritoneal metastasis of gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 20:500–503. 2017.(In Chinese). PubMed/NCBI
11	La Torre M, Rossi Del Monte S, Ferri M, Cosenza G, Mercantini P and Ziparo V: Peritoneal washing cytology in gastric cancer. How, when and who will get a benefit? A review. Minerva Gastroenterol Dietol. 57:43–51. 2011.PubMed/NCBI
12	Abe S, Yoshiwara H, Tabata H, Tachibana M, Monden N, Nakamura T and Nagaoka S: Curative resection of gastric cancer: Limitation of peritoneal lavage cytolology in predicating the outcome. J Surg Oncol. 59:226–229. 1995. View Article : Google Scholar : PubMed/NCBI
13	Wang H, Wang L, Wu Z, Sun R, Jin H, Ma J, Liu L, Ling R, Yi J, Wang L, et al: Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol. 31:2982014. View Article : Google Scholar : PubMed/NCBI
14	Ma GJ, Gu RM, Zhu M, Wen X, Li JT, Zhang YY, Zhang XM and Chen SQ: Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac J Cancer Prev. 14:7551–7554. 2013. View Article : Google Scholar : PubMed/NCBI
15	Deng D, Liu Z and Du Y: Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet. 71:125–176. 2010. View Article : Google Scholar : PubMed/NCBI
16	Grady WM and Tewai M: The next thing in prognostic molecular markers: MicroRNA signatures of cancer. Gut. 59:706–708. 2010. View Article : Google Scholar : PubMed/NCBI
17	Kowal J, Tkach M and Thery C: Biogenesis and secretion of exosome. Curr Opin Cell Biol. 29:116–125. 2014. View Article : Google Scholar : PubMed/NCBI
18	Palma J, Yaddannapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML and Duelli DM: MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 40:9125–9138. 2012. View Article : Google Scholar : PubMed/NCBI
19	Silva M and Melo SA: Non-coding RNAs in exosomes: New players in cancer biology. Curr Genomics. 16:295–303. 2015. View Article : Google Scholar : PubMed/NCBI
20	Simons M and Raposo G: Exosomes-vesicular carriers for intercelluar communication. Curr Opin Cell Biol. 21:575–581. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ge Q, Zhou Y, Lu J, Bai Y, Xie X and Lu Z: MiRNA in plasma exosome is stable under different storage conditions. Molecules. 19:1567–1575. 2014. View Article : Google Scholar
22	Hannafon BN and Ding WQ: Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 14:14240–14269. 2013. View Article : Google Scholar : PubMed/NCBI
23	Dejima H, Iinuma H, Kanaoka R, Matsutani N and Kawamura K: Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 13:1256–1263. 2017. View Article : Google Scholar : PubMed/NCBI
24	Tsukamoto M, Iinuma H, Yagi T, Matsuda K and Hashiguchi Y: Circulating exosomal microRNA-21 as a biomarker in each tumor stage of colorectal cancer. Oncology. 92:360–370. 2017. View Article : Google Scholar : PubMed/NCBI
25	Kanaoka R, Iinuma H, Dejima H, Sakai T, Uehara H, Matsutani N and Kawamura M: Usefulness of plasma exosomal microRNA-451a as a noninvasive biomarker for early prediction of recurrence and prognosis of non-small cell lung cancer. Oncology. 94:311–323. 2018. View Article : Google Scholar : PubMed/NCBI
26	Takahasi K, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M, Ikeda Y, Shibuya M, Miura F and Sano K: Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 25:155–161. 2018. View Article : Google Scholar : PubMed/NCBI
27	Kumata Y, Iinuma H, Suzuki Y, Tsukahara D, Midorikawa H, Igarashi Y, Soeda N, Kiyokawa T, Horikawa M and Fukushima R: Exosome-encapsulated microRNA-23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage. Oncol Rep. 40:319–330. 2018.PubMed/NCBI
28	Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, Papotti M and Cassoni P: Eighth edition of the UICC classification of malignant tumours: An overview of the changes in the pathological TNM classification criteria-what has changed and why? Virchows Arch. 472:519–531. 2018. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Cheng L, Sharples RA, Scicluna BJ and Hill AF: Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 3:237432014. View Article : Google Scholar
31	Sun Z, Chen C, Su Y, Wang W, Yang S, Zhou Q, Wang G, Li Z, Song J, Zhang Z, et al: Regulatory mechanisms and clinical perspectives of circRNA in digestive system neoplasms. J Cancer. 10:2885–2891. 2019. View Article : Google Scholar : PubMed/NCBI
32	Huang S, Wang J, Li J, Luo Q, Zhao M, Zheng L, Dong X, Chen C, Che Y, Liu P, et al: Serum microRNA expression profile as a diagnostic panel for gastric cancer. Jpn J Clin Oncol. 46:811–818. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, Dai J, Ma H, Hu Z, Shen H, et al: A five-microRNA panel in plasma was identified as a potential biomarker for early detection of gastric cancer. Br J Cancer. 110:2291–2299. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhao G, Jiang T, Liu Y, Huai G, Lan C, Li G, Jia G, Wang K and Yang M: Droplet digital PCR-based circulating microRNA detection serves as a promising diagnostic method for gastric cancer. BMC Cancer. 18:6762018. View Article : Google Scholar : PubMed/NCBI
35	Huang Z, Zhu D, Wu L, He M, Zhou X, Zhang L, Zhang H, Wang W, Zhu J, Cheng W, et al: Six serum-based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev. 26:188–196. 2017. View Article : Google Scholar : PubMed/NCBI
36	Komatsu S, Ichikawa D, Tsujiura M, Konishi H, Takeshita H, Nagata H, Kawaguchi T, Hirajima S, Arita T, Shiozaki A, et al: Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 33:271–276. 2013.PubMed/NCBI
37	Zheng Y, Cui L, Sun W, Zhou H, Yuan X, Huo M, Chen J, Lou Y and Guo J: MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark. 10:71–77. 2011-2012. View Article : Google Scholar
38	Liu HN, Wu H, Tseng YJ, Chen YJ, Zhang DY, Zhu L, Dong L and Shen XZ: Serum microRNA signatures and metabolomics have high diagnostic value in gastric cancer. BMC Cancer. 18:4152018. View Article : Google Scholar : PubMed/NCBI
39	Rana S, Malinowska K and Zöller M: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15:281–295. 2013. View Article : Google Scholar : PubMed/NCBI
40	Xu Y, Luo F, Liu Y, Shi L, Lu X, Xu W and Liu Q: Exosomal miR-21 derived from arsenite-transformed human bronchial epithelial cells promotes cell proliferation associated with arsenite carcinogenesis. Arch Toxicol. 89:1071–1082. 2015. View Article : Google Scholar : PubMed/NCBI
41	Jiang J, Yang P, Guo Z, Yang R, Yang H, Yang F, Li L and Xiang B: Overexpression of microRNA-21 strengthens stem cell-like characteristics in a hepatocellular carcinoma cell line. World J Surg Oncol. 14:2782016. View Article : Google Scholar : PubMed/NCBI
42	Shin VY, Siu MT, Liu X, Ng EKO, Kwong A and Chu KM: MiR-92 suppresses proliferation and induces apoptosis by targeting EP4/Notch1 axis in gastric cancer. Oncotarget. 9:24209–24220. 2018. View Article : Google Scholar : PubMed/NCBI
43	Mattick JS and Makunin IV: Non-coding RNA. Hum Mol Genet. 15:R17–R29. 2006. View Article : Google Scholar : PubMed/NCBI
44	Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
45	Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, Sugihara K and Mori M: Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol. 36:1089–1095. 2010.PubMed/NCBI
46	Cao Z, Yoon JH, Nam SW, Lee JY and Park WS: PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J Cancer Res Clin Oncol. 138:611–619. 2012. View Article : Google Scholar : PubMed/NCBI